Saturday 17 October 2026
Export SYRA’s income statement to Excel — free account
Syra Health Corp.
SYRA Healthcare Medical Care Facilities
Syra Health Corp.’s revenue for fiscal 2025 (year ended December 2025) was $7.2 million, down 9.47% from fiscal 2024. In the quarter to June 2026, revenue grew 23.0%, EPS grew 477.4% and free cash flow fell 892.7%, each against the same quarter a year earlier.
0.84
0.00
0.00%
Follow SYRA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 64.00 |
P/S ratio |
0.14 | 0.15 | 0.34 | 1.04 | |
P/FCF ratio |
0.00 | 0.00 | 3.50 | 81.00 | |
P/Operating CF |
(4.40) | (3.69) | 1.93 | (11.73) | |
P/B ratio |
0.49 | 0.51 | 1.11 | 3.20 | |
Price to Tangible BV |
0.49 | 0.51 | 1.11 | 3.20 | |
EV/Sales |
0.11 | 0.17 | 0.19 | 1.00 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 95.88 | |
EV/Operating CF |
(2.29) | (2.70) | 1.93 | 73.51 | |
EV/FCF |
(2.22) | (2.66) | 1.95 | 77.46 | |
Quick Ratio |
2.75 | 3.75 | 2.40 | 3.00 | |
Current Ratio |
3.05 | 4.06 | 2.48 | 3.13 | |
Net Debt/EBITDA |
8.71 | 12.10 | (15.22) | (8.42) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.95 | 2.24 | 1.99 | 2.22 | |
Operating CF/Net income |
1.08 | 2.15 | 5.65 | (2.87) | |
Capex/Depreciation |
0.00 | (0.04) | 0.00 | 0.00 | |
Interest Coverage |
(122.21) | (31.56) | 76.40 | 114.36 | |
Research and Development Expense of Revenue |
0.05% | 0.01% | 0.30% | 1.98% | |
Selling, General and Administrative Expense of Revenue |
34.88% | 32.72% | 25.74% | 26.25% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
1.25% | 1.35% | 1.02% | 0.88% | |
Graham Net Nets |
2.01 | 1.93 | 0.89 | 0.30 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.21 | |
Earnings Yield |
(128.11%) | (83.67%) | (6.95%) | 1.56% | |
Free Cash Flow Yield |
(35.77%) | (42.49%) | 28.57% | 1.23% | |
Revenue per Share |
0.14 | 0.15 | 0.19 | 0.18 | |
Operating CF per Share |
(0.02) | (0.02) | 0.11 | (0.05) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.02) | (0.02) | 0.11 | (0.05) | |
Cash per Share |
0.17 | 0.14 | 0.24 | 0.16 | |
Shareholders Equity per Share |
0.19 | 0.18 | 0.20 | 0.20 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.19 | 0.18 | 0.20 | 0.20 | |
Free Cash Flow |
(0.24) | (0.29) | 1.36 | (0.72) | |
Working Capital |
2.16 | 2.06 | 2.35 | 2.55 | |
Capital Expenditures |
— | 0.00 | — | — | |
Net Current Asset Value |
2.16 | 2.06 | 2.35 | 2.55 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 107.95 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 112.88 | |
| Other line items | |||||
Average Receivables |
0.91 | 0.80 | 0.91 | 1.18 | |
Average Payables |
0.27 | 0.17 | 0.35 | 0.38 | |
Average Assets |
3.84 | 3.23 | 3.83 | 3.65 | |
Average Common Equity |
2.77 | 2.49 | 2.41 | 2.52 |
Columns are period end dates